Phase 2 Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- The person joining (or their legal representative) must be able to understand the study and be willing to sign a consent form
- Adults aged 18 years or older, of any gender
- People who are reasonably physically functional — not severely limited in daily activities (confirm with trial site for the specific fitness scale used)
- People whose cancer can be measured on scans, following a standard measurement method called RECIST 1.1
- Women who could potentially become pregnant must have a negative blood pregnancy test within one month before treatment begins
- People with a confirmed diagnosis of Stage IIIA or IIIB non-small cell lung cancer (a specific type and stage of lung cancer), proven through laboratory testing of tissue
- People with no signs of cancer spread (metastasis) shown on a PET/CT scan
- People who have had a brain scan (preferably MRI with contrast dye, or CT with contrast if MRI is not medically possible) that shows no cancer in the brain
- If fluid is present around the lungs, it must have been tested and shown to contain no cancer cells — though if the fluid is too small to safely drain, the person may still be eligible
- Women who could become pregnant, and men whose partners could become pregnant, must agree to use approved contraception or abstain from sex during the study and for 90 days after treatment ends
- People whose liver, kidneys, and other organs are functioning adequately, based on blood test results
Who may not be able to join:
- People who are currently using, or plan to use, other cancer treatments or experimental drugs during the study
- People with a psychiatric illness or personal circumstances that would make it difficult to follow the study requirements
- People with serious or unstable conditions affecting the lungs, heart, liver, or kidneys that could interfere with the study, as assessed by the treating doctor
- People who are pregnant or breastfeeding
- People with active connective tissue diseases, such as active lupus or scleroderma
- People known to have HIV or AIDS
- People with a known allergic reaction to any ingredient in the study medications
- People who have had a serious active infection (viral, bacterial, or fungal, at a significant severity level) within 2 weeks before the first dose of the study treatment
- People who have previously had radiation therapy to the chest area
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Krishna Reddy, MD, PhD, University of Kansas Medical Center
Phone: 913-588-3671
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Locoregional control (LRC)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.